RE:RE:RE:RE:RE:POC in humans has been acheived is that itI have not spoken with management. Just my expectation that if they had really impressive, market moving efficacy data they would have already announced it. If they had great data, it would be in their interests and ours for them to shout it from the mountaintop as soonas they could, push the share price up and maybe raise money of it to at elast pay the $40 million tracnhe of MArathon debt off in its entirety and/or fund further progress on TH-1902 testing without a partner. So, I am sure we will get some efficacy data on the long term patients on the lower dose (300mg) but I am thinking it will be slightly intriguing at best. Let's hope I am wrong and it is shockingly good efficacy data. From what we have already seen in this regard, I imagine any new data will show that for a couple of patients their cancer continued to largely remained in check fro an extended period of time. THat did not seem to be an impressive finding when it was first announced but maybe an even longer period of time with cancer being held back, it will get more attention.
Saurus100 wrote: Rusty, With all due respect, the press release's title and content say, "It will present long-term efficacy, safety, and pharmacokinetic (PK) data." Therefore, I expect new information regarding long-term efficacy, aren't you? I agree with all of you; we have been disappointed many times... But when you say the data they will present is not focused on efficacy, is that a feeling you have, or is it based on a conversation you had with management?